Prognostic factors and predictive models in renal cell carcinoma: a contemporary review.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Urology

• Publication date

  2011-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.eururo.2011.06.041PMID 21741163
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria.

  2011cited by this paper
• Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.

  2010cited by this paper
• Percent microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma.

  2010cited by this paper
• Limited prognostic value of tumor necrosis in patients with renal cell carcinoma.

  2010cited by this paper
• The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC).

  2010cited by this paper
• Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib.

  2010cited by this paper
• Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma.

  2010cited by this paper
• Erratum: Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection (BJU International (2009) 103 (1368-1374))

  2010cited by this paper
• Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma.

  2010cited by this paper
• Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.

  2010cited by this paper
• Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma.

  2010cited by this paper
• Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy

  2009cited by this paper
• Proteomic characterization of HIV-modulated membrane receptors, kinases and signaling proteins involved in novel angiogenic pathways

  2009cited by this paper
• Conditional survival predictions after nephrectomy for renal cell carcinoma.

  2009cited by this paper
• Impact of clinical factors, including a point‐of‐care nuclear matrix protein‐22 assay and cytology, on bladder cancer detection

  2009cited by this paper
• CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma

  2009cited by this paper
• Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score.

  2009cited by this paper
• The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase‐2 expression in clear cell renal cell carcinoma

  2009cited by this paper
• Analysis of PTEN and HIF‐1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon‐α

  2009cited by this paper
• Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis.

  2009cited by this paper
• Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

  2009cited by this paper
• Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma.

  2009cited by this paper
• Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification : the TNM-C score

  2009cited by this paper
• The ‘Stage, Size, Grade and Necrosis’ score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer‐specific survival in patients with clear cell renal cell carcinoma

  2009cited by this paper
• Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

  2009influential reference
• Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.

  2009cited by this paper
• A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma.

  2009cited by this paper
• Development and evaluation of BioScore

  2009cited by this paper
• Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population: A 15‐year single center experience

  2009cited by this paper
• Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study

  2009cited by this paper
• Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification.

  2009cited by this paper
• Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC).

  2009cited by this paper
• Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma

  2008cited by this paper
• External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma

  2008cited by this paper
• Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

  2008cited by this paper
• Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma.

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

  2008cited by this paper
• Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

  2008cited by this paper
• Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma

  2008cited by this paper
• Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma

  2008cited by this paper
• Renal mass biopsy--a renaissance?

  2008cited by this paper
• Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.

  2008cited by this paper
• von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

  2008cited by this paper
• Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor

  2008cited by this paper
• Hypoxia-inducible factor (HIF) 1{alpha} and 2{alpha} levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC)

  2008cited by this paper
• Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy

  2008cited by this paper
• Preoperative nomogram predicting 12-year probability of metastatic renal cancer.

  2008cited by this paper
• Mathematical Models for Prognostic Prediction in Patients with Renal Cell Carcinoma

  2008cited by this paper
• Survivin Expression in Renal Cell Carcinoma

  2008cited by this paper
• Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer.

  2008cited by this paper
• Combination of Quantitative IMP3 and Tumor Stage: A New System to Predict Metastasis for Patients with Localized Renal Cell Carcinomas

  2008cited by this paper
• Patients with renal cell carcinoma nodal metastases can be accurately identified: External validation of a new nomogram

  2007cited by this paper
• Tumor-Infiltrating Foxp3−CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma

  2007cited by this paper
• Caveolin‐1 overexpression is associated with aggressive prostate cancer recurrence

  2007cited by this paper
• Prognostic relevance of the mTOR pathway in renal cell carcinoma

  2007cited by this paper
• Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma

  2007cited by this paper
• Hypoxia-Inducible Factor 1α in Clear Cell Renal Cell Carcinoma

  2007cited by this paper
• Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) -targeted therapy in metastatic renal cell carcinoma (RCC)

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy

  2007cited by this paper
• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

  2007cited by this paper
• Ki‐67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other

  2007cited by this paper
• Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.

  2007cited by this paper
• Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.

  2007cited by this paper
• Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival.

  2007cited by this paper
• Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma.

  2007cited by this paper
• Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases.

  2007cited by this paper
• Five‐year survival after surgical treatment for kidney cancer

  2007cited by this paper
• Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis.

  2007cited by this paper
• Multi-institutional validation of a new renal cancer-specific survival nomogram.

  2007cited by this paper
• C‐reactive protein is an informative predictor of renal cell carcinoma‐specific mortality

  2007cited by this paper
• Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.

  2007cited by this paper
• Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram

  2007cited by this paper
• Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score.

  2007cited by this paper
• Evaluation of peri‐operative peripheral and renal venous levels of pro‐ and anti‐angiogenic factors and their relevance in patients with renal cell carcinoma

  2007cited by this paper
• Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality.

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Identifizierung von Biomarkern und therapeutischen Targets beim Nierenzellkarzinom mittels ProteinChip-Technologie

  2006cited by this paper
• Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric Adenocarcinomas

  2006cited by this paper
• Impact of immune parameters on long-term survival in metastatic renal cell carcinoma.

  2006cited by this paper
• Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel‐Lindau gene status

  2006cited by this paper
• Increasing expression of fascin in renal cell carcinoma associated with clinicopathological parameters of aggressiveness.

  2006cited by this paper
• Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique.

  2006cited by this paper
• Regulatory T cells in cancer.

  2006cited by this paper
• Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

  2006cited by this paper
• Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray.

  2006cited by this paper
• Akt signaling and cancer: surviving but not moving on.

  2006cited by this paper
• [Identification of biomarkers and therapeutic targets for renal cell cancer using ProteinChip technology].

  2006cited by this paper
• Hypoxia-Inducible Factor 1α Expression in Renal Cell Carcinoma Analyzed by Tissue Microarray

  2006cited by this paper
• Role of Carbonic Anhydrases in the Progression of Renal Cell Carcinoma Subtypes: Proposal of a Unified Hypothesis

  2006cited by this paper
• Strong significant correlation between MMP-9 and systemic symptoms in patients with localized renal cell carcinoma.

  2006cited by this paper
• Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors.

  2006cited by this paper
• Monocytes and neutrophils as ‘bad guys’ for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma – results from a randomised phase II trial

  2006cited by this paper
• High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma

  2006cited by this paper
• Prognostic value of thrombocytosis in renal cell carcinoma.

  2006cited by this paper
• Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study.

  2006cited by this paper
• Costimulatory molecule B7‐H1 in primary and metastatic clear cell renal cell carcinoma

  2005cited by this paper

• MAGI3 enhances sensitivity to sunitinib in renal cell carcinoma by suppressing the MAS/ERK axis and serves as a prognostic marker

  2025cites this paper
• Accuracy of CT-Based Radiomics Models for Preoperative Grading of Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.

  2025cites this paper
• Activation of RHO-GTPase gene pattern correlates with adverse clinical outcome and immune microenvironment in clear cell renal cell carcinoma

  2025cites this paper
• Disclosing the development and focus of sequencing and omics studies in kidney neoplasm research

  2025cites this paper
• Clinicopathological-based nomogram prediction and molecular characterization of postoperative recurrence in clinical T1 clear cell renal cell carcinoma

  2025cites this paper
• Predicting Grade and Patient Survival in Renal Cancer Using Machine Learning Analysis of Nucleolar Prominence

  2025cites this paper
• Predictive modeling for metastasis in oncology: current methods and future directions

  2025cites this paper
• A preoperative CT-based radiological score for predicting recurrence in papillary renal cell carcinoma: a multicenter validation study

  2025cites this paper
• Survival Prediction for Postoperative Patients With Kidney Cancer Based on Computed Tomography Radiomics: Retrospective Cohort Study

  2025cites this paper
• Glycogen metabolism genes as a molecular signature for subtyping, prognostic prediction, and immunotherapy selection in clear cell renal cell carcinoma

  2025cites this paper
• Potential of AI and ML in oncology research including diagnosis, treatment and future directions: A comprehensive prospective

  2025cites this paper
• Oncological Results After Accidental Tumor Incision During Partial Nephrectomy

  2025cites this paper
• Using Latent Dirichlet Allocation Topic Modeling to Uncover Latent Research Topics and Trends in Renal Cell Carcinoma: Bibliometric Review

  2025cites this paper
• Recurrencia Local Post Nefrectomia en Carcinoma de Células Claras Localizado. Diferenciación Sarcomatoide: Revisión de Literatura a Propósito de Dos Casos

  2025cites this paper
• Adjuvant therapy in renal cell carcinoma: Tyrosine kinase inhibitor versus immune checkpoint inhibitor

  2024cites this paper
• Concordance between renal tumour biopsy and robotic-assisted partial and radical nephrectomy histology: a 10-year experience

  2024cites this paper
• MOF-Based Platform for Kidney Diseases: Advances, Challenges, and Prospects

  2024cites this paper
• Risk of isolated metastatic disease outside the abdomen is low in cT1a renal cancer: A retrospective analysis of a large cohort from the Scottish Renal Cancer Consortium

  2024cites this paper
• Utility of Chemical Shift Imaging and Diffusion-weighted Images/Apparent Diffusion Coefficient Maps as a Tool for Evaluation of Solid Renal Tumors.

  2024cites this paper
• Evaluation of prognostic factors for late recurrence in clear cell renal carcinoma: an institutional study

  2024cites this paper
• Tissue-Based Biomarkers Important for Prognostication and Management of Genitourinary Tumors, Including Surrogate Markers of Genomic Alterations.

  2024cites this paper
• The effect of tumor laterality on prognosis in metastatic renal cell carcinoma

  2024cites this paper
• Development and External Validation of Nomograms for Predicting Disease-Free Survival and Overall Survival in Patients with cT1-ccRCC After Partial Nephrectomy: A Multicenter Retrospective Study

  2024cites this paper
• The prognostic value of visible hematuria is only significant in T1a renal cell carcinoma: a single-center retrospective study

  2024cites this paper
• Artificial Intelligence in Renal Cell Carcinoma Histopathology: Current Applications and Future Perspectives

  2023cites this paper
• Multi-phase-combined CECT radiomics models for Fuhrman grade prediction of clear cell renal cell carcinoma

  2023cites this paper
• Recent Advances in the Management of Clear Cell Renal Cell Carcinoma: Novel Biomarkers and Targeted Therapies

  2023cites this paper
• The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype

  2023cites this paper
• Radiomics and Ki-67 index predict survival in clear cell renal cell carcinoma.

  2023cites this paper
• T1a Renal Cell Carcinoma With Metastasis: Japanese Society of Renal Cancer Retrospective Multi-institute Results

  2023cites this paper
• Comparison and validation of different risk models for papillary renal cell carcinoma.

  2023cites this paper
• PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score

  2023cites this paper
• Biomarkers in renal cell carcinoma and their targeted therapies: a review

  2023cites this paper
• Tumori renali

  2023cites this paper
• Renal cell carcinoma unsightly causing anemia and reactive thrombocytosis

  2023cites this paper
• Tumores renales

  2023cites this paper
• Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma.

  2023cites this paper
• Stereotactic body radiation therapy (SBRT): a new treatment option in renal cancer.

  2023cites this paper
• Tumeurs du rein

  2023cites this paper
• The Four-Feature Prognostic Models for Cancer-Specific and Overall Survival after Surgery for Localized Clear Cell Renal Cancer: Is There a Place for Inflammatory Markers?

  2022influential citation
• Long-term outcome of renal cell carcinoma in patients with HIV who undergo surgery

  2022cites this paper
• Diagnostics and prognostic evaluation in renal cell tumors: the German S3 guidelines recommendations

  2022cites this paper
• Diagnosing, Typing, and Staging of Renal Cell Carcinoma by Designer Matrix-Based Urinary Metabolic Analysis.

  2022cites this paper
• The significance of CD14 in clear cell renal cell carcinoma progression and survival prognosis

  2022cites this paper
• Methylation of PCDH17 and NEFH as prognostic biomarker for nonmetastatic RCC: A cohort study

  2022cites this paper
• Radiogenomics in Clear Cell Renal Cell Carcinoma: A Review of the Current Status and Future Directions

  2022cites this paper
• Long-Term Oncological and Functional Outcomes After Robot-Assisted Partial Nephrectomy for Clinically Localized Renal Cell Carcinoma

  2022cites this paper
• Heterogeneity of Hippo signalling activity in different histopathologic subtypes of renal cell carcinoma

  2022cites this paper
• Editorial: Influences in the progression of renal cell carcinoma

  2022cites this paper
• Re: Palacios AR, Schmeusser BN, Midenberg E, et al. Resection of retroperitoneal tumors with inferior vena cava involvement without caval reconstruction. J Surg Oncol. 2022. doi:10.1002/jso.27052.

  2022cites this paper
• Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma.

  2022cites this paper
• Nomograms for predicting overall and cancer-specific survival of patients with chromophobe renal cell carcinoma after nephrectomy: a retrospective SEER-based study

  2022cites this paper
• Prognostic Significance of C-reactive Protein in Patients With Non-metastatic Papillary Renal Cell Carcinoma: Results from the INternational Marker Consortium for Renal Cancer (INMARC) Cohort.

  2022cites this paper
• Markers of local kidney cancer recurrence: A surgeon’s mistake or a pattern? Review

  2022cites this paper
• Prognostic nutritional index as a prognostic factor for renal cell carcinoma: A systematic review and meta-analysis

  2022cites this paper
• Development and validation of a prognostic nomogram for predicting cancer-specific survival in patients with metastatic clear cell renal carcinoma: A study based on SEER database

  2022cites this paper
• Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy

  2021cites this paper
• A Nomogram Predicting the Prognosis of Renal Cell Carcinoma Patients with Lung Metastases

  2021cites this paper
• Identification of a Risk Stratification Model to Predict Overall Survival and Surgical Benefit in Clear Cell Renal Cell Carcinoma With Distant Metastasis

  2021cites this paper
• Preoperative anaemia and thrombocytosis predict adverse prognosis in non‐metastatic renal cell carcinoma with tumour thrombus

  2021influential citation
• Is preoperative neutrophil-to-lymphocyte ratio a red flag which can predict high-risk pathological characteristics in renal cell carcinoma?

  2021influential citation
• Construction autophagy-related prognostic risk signature combined with clinicopathological validation analysis for survival prediction of kidney renal papillary cell carcinoma patients

  2021cites this paper
• The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors

  2021cites this paper
• Prognostic role of bland thrombus in patients treated with resection of renal cell carcinoma with inferior vena cava tumor thrombus.

  2021cites this paper
• Risk models for recurrence and survival after kidney cancer: a systematic review

  2021cites this paper
• Evaluation of Factors Influencing Survival in Metastatic Renal Cell Cancer

  2021cites this paper
• Urologic Cancer Molecular Biology

  2021cites this paper
• Potential Clinical Value of Pretreatment De Ritis Ratio as a Prognostic Biomarker for Renal Cell Carcinoma

  2021cites this paper
• A Mitochondrial Dysfunction and Oxidative Stress Pathway-Based Prognostic Signature for Clear Cell Renal Cell Carcinoma

  2021cites this paper
• High RSK4 expression constitutes a predictor of poor prognosis for patients with clear cell renal carcinoma.

  2021cites this paper
• Radiomics Analysis of Contrast-Enhanced CT Predicts Survival in Clear Cell Renal Cell Carcinoma

  2021cites this paper
• Development and Validation of a Radiomic Nomogram for Predicting the Prognosis of Kidney Renal Clear Cell Carcinoma

  2021cites this paper
• Potential prognostic value of miRNAs as biomarker for progression and recurrence after nephrectomy in renal cell carcinoma: a literature review

  2021cites this paper
• Transcription Factors BARX1 and DLX4 Contribute to Progression of Clear Cell Renal Cell Carcinoma via Promoting Proliferation and Epithelial–Mesenchymal Transition

  2021cites this paper
• STAM Prolongs Clear Cell Renal Cell Carcinoma Patients' Survival via Inhibiting Cell Growth and Invasion

  2021cites this paper
• Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art

  2021cites this paper
• Promising Biomarkers in Renal Cell Carcinoma

  2021cites this paper
• Effect of radiomics from different virtual monochromatic images in dual-energy spectral CT on the WHO/ISUP classification of clear cell renal cell carcinoma.

  2021cites this paper
• Establishment and Validation of Coagulation Factor-Based Nomogram for Predicting the Recurrence-Free Survival of Prostate Cancer

  2021cites this paper
• Functional and Oncological Value of Laparoscopic Radical Nephrectomy in the Treatment of Parenchymal Renal Tumors

  2020cites this paper
• Human Epididymis Protein 4 expression in the renal cortex tissue is an independent prognostic factor in patients with renal cell carcinoma

  2020cites this paper
• CMAR_A_264856 8481..8490

  2020cites this paper
• An eleven metabolic gene signature-based prognostic model for clear cell renal cell carcinoma

  2020cites this paper
• Novel survival nomograms for patients with lung metastatic clear cell renal cell carcinoma

  2020influential citation
• Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma.

  2020cites this paper
• Prognostic Role of Prothrombin Time Activity, Prothrombin Time, Albumin/Globulin Ratio, Platelets, Sex, and Fibrinogen in Predicting Recurrence-Free Survival Time of Renal Cancer

  2020cites this paper
• MicroRNA profile in stage I clear cell renal cell carcinoma predicts progression to metastatic disease.

  2020cites this paper
• Predictive and Prognostic Markers for Cancer Medicine

  2020cites this paper
• Downregulation of ubiquitin-specific protease 2 possesses prognostic and diagnostic value and promotes the clear cell renal cell carcinoma progression

  2020influential citation
• Limited utility of qPCR-based detection of tumor-specific circulating mRNAs in whole blood from clear cell renal cell carcinoma patients

  2020cites this paper
• Abscopal effect following nivolumab induction in a patient with metastatic renal cell carcinoma-unique pathological features of the primary specimen: A case report

  2020cites this paper
• Computed tomography features predicting aggressiveness of malignant parenchymal renal tumors suitable for partial nephrectomy: a review.

  2020cites this paper
• Pre-treatment De Ritis ratio serves as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis

  2020cites this paper
• The Biological Context of C-Reactive Protein as a Prognostic Marker in Renal Cell Carcinoma: Studies on the Acute Phase Cytokine Profile

  2020cites this paper
• Nomogram Based on microRNA Signature Contributes to Improve Survival Prediction of Clear Cell Renal Cell Carcinoma

  2020cites this paper
• The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.

  2020cites this paper
• Preoperative Anemia and Thrombocytosis Predict Adverse Prognosis in Non-Metastatic Renal Cell Carcinoma With Tumor Thrombus

  2020cites this paper
• Prediction models for clear cell renal cell carcinoma ISUP/WHO grade: comparison between CT radiomics and conventional contrast-enhanced CT.

  2020cites this paper
• [Clinical and pathological analysis of small renal cell carcinoma].

  2019cites this paper
• Prognostic significance of laterality in renal cell carcinoma: A population‐based study from the surveillance, epidemiology, and end results (SEER) database

  2019cites this paper